TY - JOUR AU - Jemal, A. AU - Siegel, R. AU - Ward, E. AU - Hao, Y. AU - Xu, J. AU - Thun, M. J. PY - 2009 DA - 2009// TI - Cancer statistics, 2009 JO - CA Cancer J Clin VL - 59 UR - https://doi.org/10.3322/caac.20006 DO - 10.3322/caac.20006 ID - Jemal2009 ER - TY - JOUR AU - Ferlay, J. AU - Autier, P. AU - Boniol, M. AU - Heanue, M. AU - Colombet, M. AU - Boyle, P. PY - 2007 DA - 2007// TI - Estimates of the cancer incidence and mortality in Europe in 2006 JO - Ann Oncol VL - 18 UR - https://doi.org/10.1093/annonc/mdl498 DO - 10.1093/annonc/mdl498 ID - Ferlay2007 ER - TY - JOUR AU - Koboldt, D. C. AU - Fulton, R. S. AU - McLellan, M. D. AU - Schmidt, H. AU - Kalicki-Veizer, J. AU - McMichael, J. F. PY - 2012 DA - 2012// TI - Comprehensive molecular portraits of human breast tumours JO - Nature. VL - 490 UR - https://doi.org/10.1038/nature11412 DO - 10.1038/nature11412 ID - Koboldt2012 ER - TY - JOUR AU - Curtis, C. AU - Shah, S. P. AU - Chin, S. -. F. AU - Turashvili, G. AU - Rueda, O. M. AU - Dunning, M. J. PY - 2012 DA - 2012// TI - The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups JO - Nature. VL - 486 UR - https://doi.org/10.1038/nature10983 DO - 10.1038/nature10983 ID - Curtis2012 ER - TY - JOUR AU - Rakha, E. A. AU - Green, A. R. PY - 2017 DA - 2017// TI - Molecular classification of breast cancer: what the pathologist needs to know JO - Pathology. VL - 49 UR - https://doi.org/10.1016/j.pathol.2016.10.012 DO - 10.1016/j.pathol.2016.10.012 ID - Rakha2017 ER - TY - JOUR AU - Karamouzis, M. V. AU - Badra, F. A. AU - Papavassiliou, A. G. PY - 2007 DA - 2007// TI - Breast cancer: the upgraded role of HER-3 and HER-4 JO - Int J Biochem Cell Biol VL - 39 UR - https://doi.org/10.1016/j.biocel.2006.11.017 DO - 10.1016/j.biocel.2006.11.017 ID - Karamouzis2007 ER - TY - JOUR AU - Barros, F. F. T. AU - Abdel-Fatah, T. M. A. AU - Moseley, P. AU - Nolan, C. C. AU - Durham, A. C. AU - Rakha, E. A. PY - 2014 DA - 2014// TI - Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay JO - Breast Cancer Res Treat VL - 144 UR - https://doi.org/10.1007/s10549-014-2871-4 DO - 10.1007/s10549-014-2871-4 ID - Barros2014 ER - TY - JOUR AU - Hudis, C. A. PY - 2007 DA - 2007// TI - Trastuzumab - mechanism of action and use in clinical practice JO - N Engl J Med VL - 357 UR - https://doi.org/10.1056/NEJMra043186 DO - 10.1056/NEJMra043186 ID - Hudis2007 ER - TY - JOUR AU - Vu, T. AU - Claret, F. X. PY - 2012 DA - 2012// TI - Trastuzumab: updated mechanisms of action and resistance in breast cancer JO - Front Oncol VL - 2 UR - https://doi.org/10.3389/fonc.2012.00062 DO - 10.3389/fonc.2012.00062 ID - Vu2012 ER - TY - JOUR AU - Gonzalez-Suarez, E. AU - Jacob, A. P. AU - Jones, J. AU - Miller, R. AU - Roudier-Meyer, M. P. AU - Erwert, R. PY - 2010 DA - 2010// TI - RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis JO - Nature. VL - 468 UR - https://doi.org/10.1038/nature09495 DO - 10.1038/nature09495 ID - Gonzalez-Suarez2010 ER - TY - JOUR AU - Tan, W. AU - Zhang, W. AU - Strasner, A. AU - Grivennikov, S. AU - Cheng, J. Q. AU - Hoffman, R. M. PY - 2011 DA - 2011// TI - Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling JO - Nature. VL - 470 UR - https://doi.org/10.1038/nature09707 DO - 10.1038/nature09707 ID - Tan2011 ER - TY - JOUR AU - Palafox, M. AU - Ferrer, I. AU - Pellegrini, P. AU - Vila, S. AU - Hernandez-Ortega, S. AU - Urruticoechea, A. PY - 2012 DA - 2012// TI - RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-12-0044 DO - 10.1158/0008-5472.CAN-12-0044 ID - Palafox2012 ER - TY - JOUR AU - Schramek, D. AU - Leibbrandt, A. AU - Sigl, V. AU - Kenner, L. AU - Pospisilik, J. A. AU - Lee, H. J. PY - 2010 DA - 2010// TI - Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer JO - Nature. VL - 468 UR - https://doi.org/10.1038/nature09387 DO - 10.1038/nature09387 ID - Schramek2010 ER - TY - JOUR AU - Nolan, E. AU - Vaillant, F. AU - Branstetter, D. AU - Pal, B. AU - Giner, G. AU - Whitehead, L. PY - 2016 DA - 2016// TI - RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers JO - Nat Med VL - 22 UR - https://doi.org/10.1038/nm.4118 DO - 10.1038/nm.4118 ID - Nolan2016 ER - TY - JOUR AU - Ithimakin, S. AU - Day, K. C. AU - Malik, F. AU - Zen, Q. AU - Dawsey, S. J. AU - Bersano-Begey, T. F. PY - 2013 DA - 2013// TI - HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab JO - Cancer Res VL - 73 UR - https://doi.org/10.1158/0008-5472.CAN-12-3349 DO - 10.1158/0008-5472.CAN-12-3349 ID - Ithimakin2013 ER - TY - JOUR AU - Cao, Y. AU - Luo, J. -. L. AU - Karin, M. PY - 2007 DA - 2007// TI - IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells JO - Proc Natl Acad Sci U S A VL - 104 UR - https://doi.org/10.1073/pnas.0706728104 DO - 10.1073/pnas.0706728104 ID - Cao2007 ER - TY - JOUR AU - Cao, N. AU - Li, S. AU - Wang, Z. AU - Ahmed, K. M. AU - Degnan, M. E. AU - Fan, M. PY - 2009 DA - 2009// TI - NF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance JO - Radiat Res VL - 171 UR - https://doi.org/10.1667/RR1472.1 DO - 10.1667/RR1472.1 ID - Cao2009 ER - TY - JOUR AU - Kostenuik, P. J. AU - Nguyen, H. Q. AU - McCabe, J. AU - Warmington, K. S. AU - Kurahara, C. AU - Sun, N. PY - 2009 DA - 2009// TI - Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL JO - J Bone Miner Res VL - 24 UR - https://doi.org/10.1359/jbmr.081112 DO - 10.1359/jbmr.081112 ID - Kostenuik2009 ER - TY - JOUR AU - Zoi, I. AU - Karamouzis, M. V. AU - Adamopoulos, C. AU - Papavassiliou, A. G. PY - 2016 DA - 2016// TI - RANKL signaling and ErbB receptors in breast carcinogenesis JO - Trends Mol Med VL - 22 UR - https://doi.org/10.1016/j.molmed.2016.07.009 DO - 10.1016/j.molmed.2016.07.009 ID - Zoi2016 ER - TY - JOUR AU - Cao, Y. AU - Bonizzi, G. AU - Seagroves, T. N. AU - Greten, F. R. AU - Johnson, R. AU - Schmidt, E. V. PY - 2001 DA - 2001// TI - IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development JO - Cell. VL - 107 UR - https://doi.org/10.1016/S0092-8674(01)00599-2 DO - 10.1016/S0092-8674(01)00599-2 ID - Cao2001 ER - TY - JOUR AU - Merkhofer, E. C. AU - Cogswell, P. AU - Baldwin, A. S. PY - 2010 DA - 2010// TI - Her2 activates NF-κB and induces invasion through the canonical pathway involving IKKα JO - Oncogene. VL - 29 UR - https://doi.org/10.1038/onc.2009.410 DO - 10.1038/onc.2009.410 ID - Merkhofer2010 ER - TY - JOUR AU - Minckwitz, G. AU - Procter, M. AU - Azambuja, E. AU - Zardavas, D. AU - Benyunes, M. AU - Viale, G. PY - 2017 DA - 2017// TI - Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1703643 DO - 10.1056/NEJMoa1703643 ID - Minckwitz2017 ER - TY - JOUR AU - Yi, T. AU - Lee, H. -. L. AU - Cha, J. -. H. AU - Ko, S. -. I. AU - Kim, H. -. J. AU - Shin, H. -. I. PY - 2008 DA - 2008// TI - Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling JO - J Cell Physiol VL - 217 UR - https://doi.org/10.1002/jcp.21511 DO - 10.1002/jcp.21511 ID - Yi2008 ER - TY - JOUR AU - Papanastasiou, A. D. AU - Sirinian, C. AU - Plakoula, E. AU - Zolota, V. AU - Zarkadis, I. K. AU - Kalofonos, H. P. PY - 2017 DA - 2017// TI - RANK and EGFR in invasive breast carcinoma JO - Cancer Genet VL - 216–217 UR - https://doi.org/10.1016/j.cancergen.2017.07.004 DO - 10.1016/j.cancergen.2017.07.004 ID - Papanastasiou2017 ER - TY - JOUR AU - Harbeck, N. AU - Beckmann, M. W. AU - Rody, A. AU - Schneeweiss, A. AU - Müller, V. AU - Fehm, T. PY - 2013 DA - 2013// TI - HER2 dimerization inhibitor pertuzumab - mode of action and clinical data in breast cancer JO - Breast Care VL - 8 UR - https://doi.org/10.1159/000346837 DO - 10.1159/000346837 ID - Harbeck2013 ER - TY - JOUR AU - Bailey, S. T. AU - Miron, P. L. AU - Choi, Y. J. AU - Kochupurakkal, B. AU - Maulik, G. AU - Rodig, S. J. PY - 2014 DA - 2014// TI - NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth JO - Mol Cancer Res VL - 12 UR - https://doi.org/10.1158/1541-7786.MCR-13-0206-T DO - 10.1158/1541-7786.MCR-13-0206-T ID - Bailey2014 ER - TY - JOUR AU - Biswas, D. K. AU - Shi, Q. AU - Baily, S. AU - Strickland, I. AU - Ghosh, S. AU - Pardee, A. B. PY - 2004 DA - 2004// TI - NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis JO - Proc Natl Acad Sci U S A VL - 101 UR - https://doi.org/10.1073/pnas.0403621101 DO - 10.1073/pnas.0403621101 ID - Biswas2004 ER - TY - JOUR AU - Boopalan, T. AU - Arumugam, A. AU - Parada, J. AU - Saltzstein, E. AU - Lakshmanaswamy, R. PY - 2015 DA - 2015// TI - Receptor activator for nuclear factor-κB ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis JO - Cancer Sci VL - 106 UR - https://doi.org/10.1111/cas.12571 DO - 10.1111/cas.12571 ID - Boopalan2015 ER - TY - JOUR AU - Tsubaki, M. AU - Komai, M. AU - Fujimoto, S. AU - Itoh, T. AU - Imano, M. AU - Sakamoto, K. PY - 2013 DA - 2013// TI - Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines JO - J Exp Clin Cancer Res VL - 32 UR - https://doi.org/10.1186/1756-9966-32-62 DO - 10.1186/1756-9966-32-62 ID - Tsubaki2013 ER - TY - JOUR AU - Zhang, W. AU - Tan, W. AU - Wu, X. AU - Poustovoitov, M. AU - Strasner, A. AU - Li, W. PY - 2013 DA - 2013// TI - A NIK-IKKα module expands ErbB2-induced tumor-initiating cells by stimulating nuclear export of p27/Kip1 JO - Cancer Cell VL - 23 UR - https://doi.org/10.1016/j.ccr.2013.03.012 DO - 10.1016/j.ccr.2013.03.012 ID - Zhang2013 ER - TY - JOUR AU - Chen, Y. -. J. AU - Yeh, M. -. H. AU - Yu, M. -. C. AU - Wei, Y. -. L. AU - Chen, W. -. S. AU - Chen, J. -. Y. PY - 2013 DA - 2013// TI - Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors JO - Breast Cancer Res VL - 15 UR - https://doi.org/10.1186/bcr3575 DO - 10.1186/bcr3575 ID - Chen2013 ER - TY - JOUR AU - Jiang, Z. AU - Liu, J. C. AU - Chung, P. E. D. AU - Egan, S. E. AU - Zacksenhaus, E. PY - 2014 DA - 2014// TI - Targeting HER2(+) breast cancer: the TBK1/IKKε axis JO - Oncoscience. VL - 1 UR - https://doi.org/10.18632/oncoscience.18 DO - 10.18632/oncoscience.18 ID - Jiang2014 ER - TY - JOUR AU - Pfitzner, B. M. AU - Branstetter, D. AU - Loibl, S. AU - Denkert, C. AU - Lederer, B. AU - Schmitt, W. D. PY - 2014 DA - 2014// TI - RANK expression as a prognostic and predictive marker in breast cancer JO - Breast Cancer Res Treat VL - 145 UR - https://doi.org/10.1007/s10549-014-2955-1 DO - 10.1007/s10549-014-2955-1 ID - Pfitzner2014 ER - TY - JOUR AU - Reyes, M. E. AU - Fujii, T. AU - Branstetter, D. AU - Krishnamurthy, S. AU - Masuda, H. AU - Wang, X. PY - 2017 DA - 2017// TI - Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression JO - Breast Cancer Res Treat VL - 164 UR - https://doi.org/10.1007/s10549-017-4233-5 DO - 10.1007/s10549-017-4233-5 ID - Reyes2017 ER -